|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMCC3 |
Gene summary for TMCC3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMCC3 | Gene ID | 57458 |
| Gene name | transmembrane and coiled-coil domain family 3 | |
| Gene Alias | TMCC3 | |
| Cytomap | 12q22 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | G3V207 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57458 | TMCC3 | HTA11_2992_2000001011 | Human | Colorectum | SER | 6.71e-03 | 3.90e-01 | -0.1706 |
| 57458 | TMCC3 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.59e-07 | -2.48e-01 | 0.3005 |
| 57458 | TMCC3 | A015-C-203 | Human | Colorectum | FAP | 3.80e-02 | -8.68e-02 | -0.1294 |
| 57458 | TMCC3 | A002-C-201 | Human | Colorectum | FAP | 5.81e-04 | -2.17e-01 | 0.0324 |
| 57458 | TMCC3 | A002-C-203 | Human | Colorectum | FAP | 5.34e-04 | -1.76e-01 | 0.2786 |
| 57458 | TMCC3 | A002-C-205 | Human | Colorectum | FAP | 6.24e-04 | -2.14e-01 | -0.1236 |
| 57458 | TMCC3 | A015-C-106 | Human | Colorectum | FAP | 4.18e-04 | -2.31e-01 | -0.0511 |
| 57458 | TMCC3 | A002-C-114 | Human | Colorectum | FAP | 1.34e-02 | -2.02e-01 | -0.1561 |
| 57458 | TMCC3 | A015-C-104 | Human | Colorectum | FAP | 1.26e-05 | -2.08e-01 | -0.1899 |
| 57458 | TMCC3 | A001-C-014 | Human | Colorectum | FAP | 2.23e-02 | -1.71e-01 | 0.0135 |
| 57458 | TMCC3 | A002-C-116 | Human | Colorectum | FAP | 5.20e-04 | -1.90e-01 | -0.0452 |
| 57458 | TMCC3 | A018-E-020 | Human | Colorectum | FAP | 7.66e-03 | -1.88e-01 | -0.2034 |
| 57458 | TMCC3 | F034 | Human | Colorectum | FAP | 5.17e-04 | -2.00e-01 | -0.0665 |
| 57458 | TMCC3 | CRC-1-8810 | Human | Colorectum | CRC | 3.45e-03 | -2.25e-01 | 0.6257 |
| 57458 | TMCC3 | LZE7T | Human | Esophagus | ESCC | 1.79e-03 | 1.81e-01 | 0.0667 |
| 57458 | TMCC3 | LZE24T | Human | Esophagus | ESCC | 1.00e-07 | 8.93e-02 | 0.0596 |
| 57458 | TMCC3 | P4T-E | Human | Esophagus | ESCC | 4.46e-04 | 1.01e-01 | 0.1323 |
| 57458 | TMCC3 | P5T-E | Human | Esophagus | ESCC | 5.32e-04 | 4.59e-03 | 0.1327 |
| 57458 | TMCC3 | P12T-E | Human | Esophagus | ESCC | 2.30e-09 | 7.71e-02 | 0.1122 |
| 57458 | TMCC3 | P20T-E | Human | Esophagus | ESCC | 2.26e-03 | 5.59e-03 | 0.1124 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Thyroid | PTC |  |
| Thyroid | goiters |  |
| Thyroid | ATC |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMCC3 | SNV | Missense_Mutation | c.1379N>C | p.Cys460Ser | p.C460S | Q9ULS5 | protein_coding | deleterious(0) | possibly_damaging(0.82) | TCGA-A2-A0EV-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMCC3 | SNV | Missense_Mutation | rs371831752 | c.446N>G | p.Ser149Cys | p.S149C | Q9ULS5 | protein_coding | deleterious(0.04) | possibly_damaging(0.661) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMCC3 | SNV | Missense_Mutation | c.1323N>C | p.Lys441Asn | p.K441N | Q9ULS5 | protein_coding | deleterious(0) | possibly_damaging(0.836) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| TMCC3 | SNV | Missense_Mutation | novel | c.483N>T | p.Lys161Asn | p.K161N | Q9ULS5 | protein_coding | deleterious(0) | possibly_damaging(0.463) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMCC3 | SNV | Missense_Mutation | novel | c.473A>G | p.Asp158Gly | p.D158G | Q9ULS5 | protein_coding | tolerated(0.11) | possibly_damaging(0.609) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| TMCC3 | SNV | Missense_Mutation | novel | c.424N>C | p.Glu142Gln | p.E142Q | Q9ULS5 | protein_coding | deleterious(0) | possibly_damaging(0.685) | TCGA-BH-A0B6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMCC3 | SNV | Missense_Mutation | c.1417N>G | p.Met473Val | p.M473V | Q9ULS5 | protein_coding | tolerated(1) | benign(0) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMCC3 | SNV | Missense_Mutation | c.982G>C | p.Glu328Gln | p.E328Q | Q9ULS5 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C8-A26W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | |
| TMCC3 | SNV | Missense_Mutation | c.1092N>C | p.Lys364Asn | p.K364N | Q9ULS5 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-D8-A1JN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozolum | SD | |
| TMCC3 | insertion | Nonsense_Mutation | novel | c.1240_1241insCCACAGCAGTCAGTCGTGTATGACCCTGTAACGTGGAAA | p.Cys414delinsSerThrAlaValSerArgValTerProCysAsnValGluSer | p.C414delinsSTAVSRV*PCNVES | Q9ULS5 | protein_coding | TCGA-AN-A0FT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |